Biological
MenB-FHbp vaccine clinical trials
Keep track of what changes. Save the MenB-FHbp vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2013 | 3 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 1
Often tested with
Tested in the same studies.
4CMenB vaccine (9) · Meningococcal pentavalent vaccine (3) · Meningococcal Vaccines (1)
Studies
Open first, then newest update. How each study uses MenB-FHbp vaccine is read from its arms, and is right about nine times in ten.
Testing it · 9
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsRecruitingPhase 4Emory UniversityNCT07197762Written as Trumenba
- Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of AgeCompletedPhase 4PfizerNCT04893811Written as Trumenba
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.CompletedPhase 3PfizerNCT03135834Written as rLP2086
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of AgeCompletedPhase 3PfizerNCT04440163Written as Trumenba
- A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.CompletedPhase 2PfizerNCT01323270Written as rLP2086
- Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of AgeCompletedPhase 2PfizerNCT01768117Written as rLP2086
- A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 YearsCompletedPhase 3PfizerNCT01830855Written as rLP2086
- A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.CompletedPhase 3PfizerNCT01352845Written as rLP2086
- Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in AdolescentsCompletedPhase 2PfizerNCT00387725Written as rLP2086
As the comparator · 2 — what is tested is compared with MenB-FHbp vaccine
- Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.RecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT04166656Written as Trumenba®
- Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and InfantsTerminatedPhase 1Sanofi Pasteur, a Sanofi CompanyNCT04825223Written as Multicomponent Meningococcal B Vaccine
Codes
What other systems call MenB-FHbp vaccine · ClinicalTrials.gg INT002060
- MeSH (NLM) C000729870MenB-FHbp vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729870 | MenB-FHbp vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.